Qsymia is the combination of phentermine and topiramate, an anticonvulsant drug that can cause weight loss as a side effect. The combination of topiramate and phentermine was previously prescribed off-label, meaning the combination was prescribed for weight loss without it being approved specifically for this use by the FDA, but in 2012 the FDA approved the weight loss medication Qsymia as the brand name for this combination. Qsymia is manufactured by Vivus Inc.
Qsymia is prescribed in conjunction with a program of exercise and a restricted diet to help obese individuals lose weight. It is important that patients taking Qsymia adopt new ways of eating and increased levels of exercise in order to achieve maximum weight loss. These new behaviors should be continued after the course of Qsymia has finished to avoid gaining back the weight lost.
Qsymia is a controlled substance and can be habit forming. The FDA recommends that Qsymia be used for a period of no longer than 3 months.
Qsymia is only available in capsule form. There are four different Qsymia capsules, each with different quantities of phentermine and topiramate, ranging from 3.75 mg of phentermine and 23 mg of topiramate to 15 mg of phentermine and 92 mg of topiramate.
Click here for more information about Qsymia.